1.Progress in Diagnosis and Treatment of Central Post-stroke Pain
Shujia SONG ; Chen SUN ; Lijian PEI ; Weihai XU ; Yuguang HUANG
Medical Journal of Peking Union Medical College Hospital 2024;15(2):265-271
Central post-stroke pain (CPSP), a neuropathic pain syndrome occurring after a cerebrovascular accident, is characterized by pain or paraesthesia in the part of the body dominated by the area of the brain where blood vessels are injured. CPSP patients are often accompanied by anxiety, depression and other emotional disorders, which have a serious negative impact on patients' quality of life. However, the pathogenesis of CPSP has not been fully elucidated, the clinical diagnosis rate is not high, and the commonly used treatment methods are not effective. This article reviews the clinical features, epidemiology, pathogenesis and treatment of CPSP in order to provide reference for the elucidation of CPSP mechanism and effective treatment.
2.Expert consensus of anti-tumor drugs prescription review: kidney cancer
Min LIU ; Wei MIAO ; Chao ZHANG ; Jie ZHANG ; Yuanyuan DAI ; Mei DONG ; Jiang LIU ; Hongbing HUANG ; Qing ZHAI ; Yuguo LIU ; Ting XU ; Ping HUANG ; Wenzhou ZHANG ; Gang JIANG ; Junling CAO ; Lixia WANG ; Yancai SUN ; Mingyan JIANG ; Yongning LYU ; Xiaoyang LU ; Maobai LIU ; Ningsheng LIANG ; Zhu DAI ; Yanqing SONG ; Pengmei LI ; Guangxuan LIU ; Zhiying HAO ; Dunwu YAO ; Guiru LI ; Shujia KONG ; Ruixiang XIE ; Jianhua WANG ; Qing WEI ; Lechuan JIA ; Mei LI ; Jun MENG ; Fang CAO ; Hongzhe SHI ; Dan YAN ; Zaixian BAI ; Chen WANG ; Guohui LI ; Jie HE
Adverse Drug Reactions Journal 2021;23(6):285-292
Kidney cancer usually requires multidisciplinary individualized treatments. No matter what kind of treatment, drugs are essential. According to the "six-step process" (prescription legitimacy review, patient basic information evaluation review, treatment protocol review, organ function and laboratory index review, pretreatment review, and unconventional prescription review) in prescription review proposed by the anti-tumor drug prescription review expert group and referring to domestic and foreign kidney cancer guidelines and drug instructions in recent years, this consensus selects 9 targeted drugs and 4 immunotherapeutic drugs that are currently commonly used in China and elaborates the key review points in patient basic information evaluation review, treatment protocol review, and organ function and laboratory index review of kidney cancer drug treatment, in order to provide reference for clinical front-line pharmacists to review prescriptions of kidney cancer patients and promote rational drug use in clinic.
3.Expert consensus of anti-tumor drugs prescription review: kidney cancer
Min LIU ; Wei MIAO ; Chao ZHANG ; Jie ZHANG ; Yuanyuan DAI ; Mei DONG ; Jiang LIU ; Hongbing HUANG ; Qing ZHAI ; Yuguo LIU ; Ting XU ; Ping HUANG ; Wenzhou ZHANG ; Gang JIANG ; Junling CAO ; Lixia WANG ; Yancai SUN ; Mingyan JIANG ; Yongning LYU ; Xiaoyang LU ; Maobai LIU ; Ningsheng LIANG ; Zhu DAI ; Yanqing SONG ; Pengmei LI ; Guangxuan LIU ; Zhiying HAO ; Dunwu YAO ; Guiru LI ; Shujia KONG ; Ruixiang XIE ; Jianhua WANG ; Qing WEI ; Lechuan JIA ; Mei LI ; Jun MENG ; Fang CAO ; Hongzhe SHI ; Dan YAN ; Zaixian BAI ; Chen WANG ; Guohui LI ; Jie HE
Adverse Drug Reactions Journal 2021;23(6):285-292
Kidney cancer usually requires multidisciplinary individualized treatments. No matter what kind of treatment, drugs are essential. According to the "six-step process" (prescription legitimacy review, patient basic information evaluation review, treatment protocol review, organ function and laboratory index review, pretreatment review, and unconventional prescription review) in prescription review proposed by the anti-tumor drug prescription review expert group and referring to domestic and foreign kidney cancer guidelines and drug instructions in recent years, this consensus selects 9 targeted drugs and 4 immunotherapeutic drugs that are currently commonly used in China and elaborates the key review points in patient basic information evaluation review, treatment protocol review, and organ function and laboratory index review of kidney cancer drug treatment, in order to provide reference for clinical front-line pharmacists to review prescriptions of kidney cancer patients and promote rational drug use in clinic.

Result Analysis
Print
Save
E-mail